Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

What:
Lung cancer kills more people than breast cancer, prostate cancer, kidney cancer, colon cancer, liver cancer and skin cancer combined, and it is the most common cause of cancer death.

In partnership with the International Association for the Study of Lung Cancer, the American Association for Cancer Research will host the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, which will bring together leaders from all over the world who share the goal of eradicating this form of cancer. The conference will open with a keynote lecture from Tyler Jacks, Ph.D., president of the American Association for Cancer Research and director of the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.

To help you plan your coverage of the conference, the program schedule is available online at www.aacr.org, and an electronic press kit containing the press releases and select highlighted abstracts will be available to subscribing media on Jan. 6, 2010, via Eurekalert, Newswise or by request to the AACR Communications Department.

Findings presented at the meeting will include:
•basic science on the role of microRNAs and cancer stem cells in carcinogenesis development;
•personalized therapies for long cancer—what is ready for prime time;
•new treatment strategies for the hardest to treat subsets of lung cancer; and
•groundbreaking tools for noninvasive diagnosis.

When:
Jan. 11-14, 2010

Where:
Loews Coronado Bay Resort
Coronado, Calif.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths